These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 39003106)
1. Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants. Bonnin FA; Talarico LB; Ferolla FM; Acosta PL; Phung E; Kumar A; Toledano A; Caratozzolo A; Neira P; Mascardi N; Satragno D; Contrini MM; Graham BS; Ruckwardt TJ; López EL; Vaccine; 2024 Nov; 42(25):126119. PubMed ID: 39003106 [TBL] [Abstract][Full Text] [Related]
2. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus. Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382 [TBL] [Abstract][Full Text] [Related]
3. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV. Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876 [TBL] [Abstract][Full Text] [Related]
4. Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection. Capella C; Chaiwatpongsakorn S; Gorrell E; Risch ZA; Ye F; Mertz SE; Johnson SM; Moore-Clingenpeel M; Ramilo O; Mejias A; Peeples ME J Infect Dis; 2017 Dec; 216(11):1398-1406. PubMed ID: 29029312 [TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195 [TBL] [Abstract][Full Text] [Related]
6. Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults. Ye X; Iwuchukwu OP; Avadhanula V; Aideyan LO; McBride TJ; Ferlic-Stark LL; Patel KD; Piedra FA; Shah DP; Chemaly RF; Piedra PA Front Immunol; 2019; 10():706. PubMed ID: 30984206 [No Abstract] [Full Text] [Related]
7. van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038 [TBL] [Abstract][Full Text] [Related]
8. Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection. Jounai N; Yoshioka M; Tozuka M; Inoue K; Oka T; Miyaji K; Ishida K; Kawai N; Ikematsu H; Kawakami C; Shimizu H; Mori M; Ishii KJ; Takeshita F EBioMedicine; 2017 Feb; 16():124-135. PubMed ID: 28111238 [TBL] [Abstract][Full Text] [Related]
9. Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness. Mazur NI; Horsley NM; Englund JA; Nederend M; Magaret A; Kumar A; Jacobino SR; de Haan CAM; Khatry SK; LeClerq SC; Steinhoff MC; Tielsch JM; Katz J; Graham BS; Bont LJ; Leusen JHW; Chu HY J Infect Dis; 2019 Jan; 219(1):59-67. PubMed ID: 30107412 [TBL] [Abstract][Full Text] [Related]
10. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge. Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496 [TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection. Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial. Schwarz TF; Hwang SJ; Ylisastigui P; Liu CS; Takazawa K; Yono M; Ervin JE; Andrews CP; Fogarty C; Eckermann T; Collete D; de Heusch M; De Schrevel N; Salaun B; Lambert A; Maréchal C; Olivier A; Nakanwagi P; Lievens M; Hulstrøm V J Infect Dis; 2024 Jul; 230(1):e102-e110. PubMed ID: 39052726 [TBL] [Abstract][Full Text] [Related]
13. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector. Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study. Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852 [TBL] [Abstract][Full Text] [Related]
15. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. Kim E; Okada K; Beeler JA; Crim RL; Piedra PA; Gilbert BE; Gambotto A J Virol; 2014 May; 88(9):5100-8. PubMed ID: 24574396 [TBL] [Abstract][Full Text] [Related]
16. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV. Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320 [TBL] [Abstract][Full Text] [Related]
17. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant. Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790 [TBL] [Abstract][Full Text] [Related]
18. Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles. McGinnes Cullen L; Schmidt MR; Morrison TG J Virol; 2019 May; 93(9):. PubMed ID: 30760576 [TBL] [Abstract][Full Text] [Related]
19. Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants. Koivisto K; Nieminen T; Mejias A; Capella Gonzalez C; Ye F; Mertz S; Peeples M; Ramilo O; Saxén H J Infect Dis; 2022 Apr; 225(7):1189-1196. PubMed ID: 34129040 [TBL] [Abstract][Full Text] [Related]
20. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats. Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]